Table 4 Partial FDA-approved drugs and clinical trials for the treatment of nonneoplastic diseases, including NDDs and metabolic diseases

From: p53: from understanding its structure to advances in therapeutic targeting

Diseases	Drug class	Drugs	Clinical trials	URL
Alzheimer disease	Amyloid-directed antibody	Aducanumab	NCT04241068	https://clinicaltrials.gov/search?term=NCT04241068
			NCT02484547	https://clinicaltrials.gov/search?term=NCT02484547
			NCT02434718	https://clinicaltrials.gov/search?term=NCT02434718
			NCT01677572	https://clinicaltrials.gov/search?term=NCT01677572
	Cholinesterase Inhibitors	Donepezil	NCT01539031	https://clinicaltrials.gov/search?term=NCT01539031
			NCT01063556	https://clinicaltrials.gov/search?term=NCT01063556
			NCT02097056	https://clinicaltrials.gov/search?term=NCT02097056
		Rivastigmine	NCT02063269	https://clinicaltrials.gov/search?term=NCT02063269
			NCT02989402	https://clinicaltrials.gov/search?term=NCT02989402
			NCT02444637	https://clinicaltrials.gov/search?term=NCT02444637
			NCT01399125	https://clinicaltrials.gov/search?term=NCT01399125
		Galantamine	NCT01039194	https://clinicaltrials.gov/search?term=NCT01039194
	Glutamate regulators	Memantine	NCT00322153	https://clinicaltrials.gov/search?term=NCT00322153
			NCT02553928	https://clinicaltrials.gov/search?term=NCT02553928
			NCT00551161	https://clinicaltrials.gov/search?term=NCT00551161
			NCT03703856	https://clinicaltrials.gov/search?term=NCT03703856
Parkinson disease	Dopamine supplements	Levodopa	NCT01026428	https://clinicaltrials.gov/search?term=NCT01026428
			NCT06037590	https://clinicaltrials.gov/search?term=NCT06037590
			NCT00004733	https://clinicaltrials.gov/search?term=NCT00004733
	Decarboxylase inhibitors	Carbidopa	NCT01399905	https://clinicaltrials.gov/search?term=NCT01399905
Diseases	Drug class	Drugs	Clinical trials	URL
			NCT01296464	https://clinicaltrials.gov/search?term=NCT01296464
			NCT06236230	https://clinicaltrials.gov/search?term=NCT06236230
		Apomorphine hydrochloride	NCT00610103	https://clinicaltrials.gov/search?term=NCT00610103
			NCT02006121	https://clinicaltrials.gov/search?term=NCT02006121
			NCT00200525	https://clinicaltrials.gov/search?term=NCT00200525
		Pergolide	NCT01066403	https://clinicaltrials.gov/search?term=NCT01066403
			NCT00624741	https://clinicaltrials.gov/search?term=NCT00624741
	Dopamine agonist	Pramipexole dihydrochloride	NCT04275492	https://clinicaltrials.gov/search?term=NCT04275492
			NCT00321854	https://clinicaltrials.gov/search?term=NCT00321854
		Ropinirole hydrochloride library	NCT00260793	https://clinicaltrials.gov/search?term=NCT00260793
			NCT00256854	https://clinicaltrials.gov/search?term=NCT00256854
			NCT03250117	https://clinicaltrials.gov/search?term=NCT03250117
		Rotigotine	NCT00522379	https://clinicaltrials.gov/search?term=NCT00522379
			NCT01723904	https://clinicaltrials.gov/search?term=NCT01723904
Amyotrophic Lateral Sclerosis	Glutamate-receptor antagonist	Riluzole	NCT03537807	https://clinicaltrials.gov/search?term=NCT03537807
			NCT00542412	https://clinicaltrials.gov/search?term=NCT00542412
			NCT05508074	https://clinicaltrials.gov/search?term=NCT05508074
	Free-radical scavenger	Edaravone	NCT04259255	https://clinicaltrials.gov/search?term=NCT04259255
			NCT03272802	https://clinicaltrials.gov/search?term=NCT03272802
Metabolic diseases	GLP1R agonist	Exenatide	NCT00044668	https://clinicaltrials.gov/search?term=NCT00044668
			NCT06725693	https://clinicaltrials.gov/search?term=NCT06725693
			NCT02533453	https://clinicaltrials.gov/search?term=NCT02533453
		Liraglutide	NCT01208012	https://clinicaltrials.gov/search?term=NCT01208012
			NCT00978393	https://clinicaltrials.gov/search?term=NCT00978393
		Semaglutide	NCT06634927	https://clinicaltrials.gov/search?term=NCT06634927
			NCT06739044	https://clinicaltrials.gov/search?term=NCT06739044
	DPP4 inhibitor	Sitagliptin	NCT00854035	https://clinicaltrials.gov/search?term=NCT00854035
			NCT01354990	https://clinicaltrials.gov/search?term=NCT01354990
			NCT02900417	https://clinicaltrials.gov/search?term=NCT02900417
			NCT00813228	https://clinicaltrials.gov/search?term=NCT00813228
	Thiazolidinedione	Pioglitazone	NCT02753803	https://clinicaltrials.gov/search?term=NCT02753803
			NCT00762736	https://clinicaltrials.gov/search?term=NCT00762736
			NCT01258322	https://clinicaltrials.gov/search?term=NCT01258322
		Rosiglitazone	NCT00551564	https://clinicaltrials.gov/search?term=NCT00551564
			NCT00405015	https://clinicaltrials.gov/search?term=NCT00405015
			NCT00306176	https://clinicaltrials.gov/search?term=NCT00306176
Diseases	Drug class	Drugs	Clinical trials	URL
	SGLT2 inhibitor	Canagliflozin	NCT02891954	https://clinicaltrials.gov/search?term=NCT02891954
			NCT02912455	https://clinicaltrials.gov/search?term=NCT02912455
			NCT02597309	https://clinicaltrials.gov/search?term=NCT02597309
		Dapagliflozin	NCT02891954	https://clinicaltrials.gov/search?term=NCT02891954
			NCT02912455	https://clinicaltrials.gov/search?term=NCT02912455
			NCT02597309	https://clinicaltrials.gov/search?term=NCT02597309
		Empagliflozin	NCT01581658	https://clinicaltrials.gov/search?term=NCT01581658
			NCT01316341	https://clinicaltrials.gov/search?term=NCT01316341
			NCT01907113	https://clinicaltrials.gov/search?term=NCT01907113
	FXR	Obeticholic acid	NCT02532335	https://clinicaltrials.gov/search?term=NCT02532335
			NCT01585025	https://clinicaltrials.gov/search?term=NCT01585025
			NCT03836937	https://clinicaltrials.gov/search?term=NCT03836937
		Cilofexor	NCT02654002	https://clinicaltrials.gov/search?term=NCT02654002
			NCT03987074	https://clinicaltrials.gov/search?term=NCT03987074
			NCT03449446	https://clinicaltrials.gov/search?term=NCT03449446

Back to article page

Table 4 Partial FDA-approved drugs and clinical trials for the treatment of nonneoplastic diseases, including NDDs and metabolic diseases

Search

Quick links